M2M
0.009
50%
ATC
0.001
-50%
DXN
0.395
43.6%
ARV
0.003
-25%
C7A
0.004
33.3%
RWL
0.145
-23.7%
FAU
0.008
33.3%
CHM
0.016
-20%
NXL
1.857
30.3%
ERE
0.012
-20%
ACU
0.135
28.6%
FIN
0.004
-20%
YRL
0.155
22%
CDE
0.005
-16.7%
AUQ
0.045
21.6%
ENL
0.005
-16.7%
RRE
0.11
20.9%
RLG
0.005
-16.7%
AEU
0.552
20%
KGN
3.78
-16.2%
GTN
0.24
20%
AQX
0.006
-14.3%
RGL
0.012
20%
RFT
0.006
-14.3%
WRX
0.024
20%
UNT
0.006
-14.3%
14D
0.07
16.7%
LML
0.007
-12.5%
M4M
0.007
16.7%
DTZ
0.023
-11.5%
WSR
0.007
16.7%
CST
0.072
-11.1%
CMP
0.27
14.9%
PCL
0.008
-11.1%
EUR
0.35
14.8%
RAP
0.024
-11.1%
PKY
0.039
14.7%
BDX
0.052
-10.3%
BNZ
4.25
14.6%
NHF
6.65
-10.1%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BOT U.S. FDA accepted new drug application

Botanix Pharmaceuticals’ (ASX:BOT) resubmission of its New Drug Application for Sofdra has been accepted by the U.S. FDA. As a result, approval of the gel is targeted for June 2024 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20240122/pdf/05zm3xd62ktg15.pdf #FDA #DrugApproval #ASX